Homologous Recombination Repair Pathway Gene Mutation Spectrum in Chinese Breast Cancer Patients

Homologous Recombination Repair Pathway Gene Mutation Spectrum in Chinese Breast Cancer Patients: A Multi-center, Prospective, Observational Study

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05901025

Enrollment

5000

Registered

2023-06-13

Start date

2023-06-05

Completion date

2033-06-30

Last updated

2023-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Homologous Recombination Repair Pathway, Outcome, Mutation

Brief summary

The goal of this clinical trial is to learn about the mutation spectrum of homologous recombination repair pathway genes and its instructive significance in the treatment of Chinese breast cancer patients.

Detailed description

The main questions it aims to answer are: 1. What is the mutation spectrum of homologous recombination repair pathway genes in Chinese breast cancer patients? 2. Does homologous recombination repair pathway gene mutation have an impact on patient outcome (breast cancer recurrence, neoadjuvant chemotherapy efficacy, treatment decisions, etc.) ? There is no intervention on participants, but all participants will be given regular follow-up post surgery according to ASCO guidelines.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. Pathology-confirmed breast cancer patients who meet at least one of the criteria below: * Triple-negative breast cancer * Age ≤ 50 years * Male breast cancer * With personal or family history of malignancy: breast cancer, ovarian cancer, prostate cancer, pancreatic cancer, other malignancies * HER-2 negative recurrent or metastatic breast cancer * HER-2 negative high-risk breast cancer: A: Neoadjuvant phase: non-pathological complete response for triple-negative breast cancer; non-pathological complete response AND CPS+EG score ≥ 3 for hormone receptor positive breast cancer B: Adjuvant phase: ≥ pT2 or ≥ pN1 for triple-negative breast cancer; ≥ 4 lymph node metastasis for hormone receptor positive breast cancer 2. Having been or intended to be tested for germline and (or) somatic homologous recombination repair gene mutations 3. Consent to providing medical charts and homologous recombination repair gene testing results, and being cooperative for long-term follow-up

Exclusion criteria

1. Homologous recombination repair gene testing results unavailable 2. Other factors deemed by the investigators that may sabotage the study

Design outcomes

Primary

Measure	Time frame	Description
Homologous recombination repair pathway gene mutation spectrum	At recruitment	to reveal the homologous recombination repair pathway gene mutation spectrum

Secondary

Measure	Time frame	Description
Breast cancer events	At 5 years from surgery	to compare the incidence of breast cancer-related events and deaths between patients with or without homologous recombination repair pathway gene mutation(s)
Treatment decision and appliance	At 5 years from surgery	to compare the treatment decision and appliance between patients with or without homologous recombination repair pathway gene mutation(s)

Contacts

Primary ContactYiwei Tong

ash_yiwei@sjtu.edu.cn0086-021-64370045

Backup ContactXiaosong Chen

chenxiaosong0156@hotmail.com0086-021-64370045

Outcome results